Journal
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
Volume 19, Issue 1, Pages 22-27Publisher
SAGE PUBLICATIONS INC
DOI: 10.2310/7750.2014.13151
Keywords
-
Categories
Funding
- AbbVie
- Novartis
- Actelion
- Amgen
- Astellas
- Bio-K
- Celgene
- Galderma
- Janssen
- LEO Pharma
- Merck/Schering
- Pfizer
- Roche
- Valeant
- Abbott
- Centocor
- Isotechnika
- Lilly
- Merck
- Ortho Biotech
- Wyeth
- Eli Lilly
Ask authors/readers for more resources
Objective: Explore the feasibility of Treat to Target in the area of psoriasis as seen in other therapeutic areas such as hypertension, hyperlipidemia, diabetes and rheumatoid arthritis. Methods: Review validated, measurable targets for psoriasis, including physician global assessment (PGA), psoriasis area and severity index (PASI) and dermatology life quality index (DLQI). Examine principles brought forth in the published European consensus on psoriasis and develop a Canadian consensus on Treat to Target in psoriasis. Results: As PASI and DLQI are not routinely used in the community setting, we are recommending target at a PGA of zero (clear). Conclusion: Recommend that the target is a PGA of zero (clear) as it provides a simple and measurable result that the patient and physician can clearly understand.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available